香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 和黃醫藥將於2025年歐洲腫瘤內科學會 (ESMO) 年會公佈臨床數據 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈將於2025年10月17日至21日在德國 柏林召開的歐洲腫瘤內科學會（「ESMO」）2025年年會上公佈和黃醫藥自主研發的化合物的數項研究的最新及更新 後的數據。 呋喹替尼（fruquintinib）聯合信迪利單抗（sintilimab）用於二線治療局部晚期或轉移性腎細胞癌的FRUSICA-2註 冊研究結果將於迷你口頭報告環節公佈。此外，呋喹替尼用於治療子宮內膜癌的FRUSICA-1研究，以及賽沃替尼 （savolitinib）用於治療非小細胞肺癌的SACHI和SAVANNAH研究的進一步分析結果將於海報展示環節公佈。 ...

Group 1 - The core point of the article is the appointment of Cao Dong as the new CEO of JD Health, following the resignation of Jin Enlin for family reasons [1] - Cao Dong has been with JD since January 2012 and has held various leadership roles within the financial system of JD Group, including CFO of JD Health from April 2019 to May 2023 [1] - The board of directors of JD Health will now include Cao Dong as the executive director, along with other members such as Liu Qiangdong and independent directors [1] Group 2 - JD Health reported a revenue of 35.29 billion RMB for the first half of 2025, representing a year-on-year increase of 24.5%, with a net profit of 3.57 billion RMB, up 35% [2] - For the full year of 2024, JD Health's revenue was 59.93 billion RMB, showing a year-on-year growth of 11.55%, while the net profit attributable to shareholders was 4.16 billion RMB, increasing by 94.31% [2] - As of the report date, JD Health's stock price rose by 1.63% to 65.55 HKD, with a total market capitalization of 209.86 billion HKD [2]

Core Viewpoint - The announcement of a 100% tariff on all branded/patented drugs by Trump starting in October is expected to have limited impact on China's innovative drug industry chain, with no excessive concerns warranted [1] Group 1: Impact on Innovative Drugs - Most Chinese innovative drugs that are currently being exported have either established production capacity in the U.S. or have outsourced production to local CMO companies [1] - The majority of domestic innovative drugs are exported using a business development (BD) model, which mitigates the impact of the tariff [1] Group 2: Impact on CXO Sector - The export products in the CXO sector primarily consist of raw materials and biological raw liquids, which are not affected by the new tariff; the proportion of finished dosage forms exported is low [1] - The investment timeline for multinational corporations (MNCs) to build factories in China will take time, leading to limited direct impact on CXO orders in the short term [1] - Long-term policy changes may influence the pace of factory construction by MNCs [1] Group 3: Upcoming Catalysts - The ESMO conference will take place in mid to late October, with a focus on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] - The results of medical insurance negotiations and the first version of the commercial insurance innovative drug directory are expected to be announced in October-November [1] Group 4: Mid to Long-term Recommendations - Recommended stocks in the innovative drug sector include 3SBio (01530) and Eucure Biopharma-B (06996), which have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] - Companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered undervalued with clear long-term growth logic [2] - In the CXO sector, WuXi AppTec (02268) is highlighted as a leading player benefiting from high downstream demand and improving financing conditions [2]

Group 1 - The core viewpoint is that the new 100% tariff on all branded/patented drugs announced by Trump will have limited impact on China's innovative drug industry chain, and there is no need for excessive concern [1] - For innovative drugs, most products currently being exported are either produced in the U.S. or outsourced to U.S. CMO, and most domestic innovative drugs are exported using the BD model [1] - For CXO, the main export products are raw materials and herbal extracts, which are not affected by the new tariff; the proportion of finished drug exports is low, and the investment timeline for MNC clients to build factories will take time, leading to limited short-term impact on CXO orders [1] Group 2 - Mid to long-term recommendations include innovative drugs such as 3SBio (01530) and Eucure Biopharma-B (06996), which have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] - Other recommended companies include Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech, which are considered significantly undervalued with clear long-term growth logic [2] - For CXO, companies like WuXi AppTec (02268) are expected to benefit from high downstream demand and improving financing conditions [2]

Core Insights - The report highlights that the impact of Trump's 100% tariff on imported innovative drugs may be limited, suggesting a buying opportunity during market dips [1][2] - The Chinese innovative drug industry is expected to be minimally affected, as many companies have established production capabilities in the U.S. or have outsourced to local contract manufacturing organizations (CMOs) [2] - The report recommends focusing on specific companies with significant data releases at the upcoming ESMO conference and monitoring the results of healthcare negotiations [2] Industry Overview - The U.S. tariff policy primarily targets multinational pharmaceutical companies that rely on overseas production, pushing them to establish manufacturing facilities in the U.S. [2] - The impact on the CXO sector is expected to be limited in the short term, as the majority of exports consist of raw materials and biological drug solutions, with a low proportion of finished drug exports [2] - The report indicates that the overall influence of the tariff on the Chinese pharmaceutical supply chain is manageable, contrasting with previous more aggressive statements from the Trump administration [2] Investment Recommendations - The report identifies potential catalysts for the pharmaceutical sector in Q4 2025, including the ESMO conference and the upcoming healthcare negotiation results [2] - Recommended companies for investment include Innovent Biologics, Kelun-Biotech, and Rongchang Biologics, which are expected to have significant data releases [2] - Long-term investment opportunities are suggested in innovative drug companies like 3SBio and Eucure Biopharma, which are undervalued and have clear growth trajectories [2]

Core Viewpoint - The company maintains a strong belief in the innovation drug market, viewing it as a significant trend that will last for two to three years, regardless of market fluctuations [1][16][17]. Group 1: Market Outlook - The current innovation drug market is considered to be in the first half of its cycle, supported by a three to five-year industry cycle and the global value of quality companies' mid-term product pipelines [2][32]. - The innovation drug sector is characterized by high alpha attributes, requiring selective stock picking rather than blind holding [35]. Group 2: Investment Strategy - The company emphasizes the importance of long-term holding in the innovation drug sector, suggesting that frequent tracking of short-term information may lead to losses [33][34]. - As the number of listed companies in the sector increases, the significance of stock selection ability and professional expertise will become more pronounced [36][37]. Group 3: Company Performance - The fund managed by the company has shown strong performance, with a return rate of 85.64% in the first half of the year, ranking first among equity funds [3]. - The fund's assets currently total 16.764 billion yuan, with a focus on the pharmaceutical innovation sector in the Hong Kong market [4][6]. Group 4: Competitive Landscape - The company highlights the increasing global interest in Chinese innovation drugs, driven by high efficiency, output, and cost-effectiveness in drug development [9][19]. - The trend of multinational companies increasing their investments in China is expected to continue, with a significant rise in licensing deals from Chinese firms projected for the coming years [21][22][28].

Investment Rating - The report maintains a "Buy" rating for several companies in the pharmaceutical sector, indicating an expectation of total returns exceeding the relevant industry over the next 12 months [4]. Core Insights - The recent announcement by President Trump regarding a 100% tariff on imported branded and patented drugs is expected to have a limited impact on China's innovative drug industry, as most Chinese companies either have production facilities in the U.S. or utilize local contract manufacturing organizations (CMOs) [3]. - The report suggests that investors should strategically position themselves in the innovative drug supply chain during market fluctuations, with several catalysts expected in Q4 2025, including the ESMO conference and upcoming healthcare negotiations [3]. - Long-term investment opportunities are highlighted in specific segments such as innovative drugs and CXO services, with recommendations for companies like Sanofi, Legend Biotech, and WuXi AppTec [3]. Summary by Sections Section: Impact of Tariffs - The 100% tariff on imported drugs is not expected to significantly affect Chinese innovative drug companies, as they have limited direct exports to the U.S. and often rely on local production [3]. - CXO companies primarily export raw materials and biological drugs, which are not impacted by the new tariffs, indicating a controlled overall impact on the Chinese pharmaceutical supply chain [3]. Section: Investment Recommendations - The report recommends focusing on companies with rich short-term catalysts, such as Kangfang Biotech and Rongchang Biotech, ahead of significant data releases and healthcare negotiations [3]. - Specific companies are highlighted for their growth potential, including Sanofi and Legend Biotech, which are considered undervalued with clear long-term growth logic [3]. Section: Company Ratings - A list of companies with their respective ratings and target prices is provided, showing a generally positive outlook for the majority of the companies covered [4]. - Notable companies with "Buy" ratings include Sanofi (target price of 35.00), Legend Biotech (target price of 74.00), and WuXi AppTec (target price of 70.00) [4].

Core Viewpoint - The U.S. plans to impose a 100% tariff on all branded and patented drugs starting October 1, 2023, with exemptions for companies building drug manufacturing plants in the U.S. [1][12] Drug Tariff Impact - The proposed tariff primarily targets branded pharmaceutical products and patented drugs, likely excluding generic drugs and biosimilars [2][4] - Branded drugs are typically sold under trademark names and can include both patented and off-patent products, which are often more expensive than generics [2][4] - Patented drugs are those still under patent protection, allowing only the original developer to produce and sell them [3][4] Export Data and Structure - In 2024, China's pharmaceutical exports to the U.S. are projected to reach $19.047 billion, with $6.425 billion in Western medicines and $0.87 billion in traditional Chinese medicine [4][5] - Raw materials account for 70.35% of China's pharmaceutical exports to the U.S., with $4.52 billion in raw material exports [4][5][6] Impact on Chinese Innovative Drugs - Several Chinese innovative drugs sold in the U.S. may be affected by the new tariffs, including products from companies like BeiGene and Legend Biotech [7][8] - The number of affected drugs is currently limited, with only a few Chinese companies having received FDA approval for their products [7][8] Global Manufacturing Trends - The new tariff policy is seen as an attempt to encourage pharmaceutical manufacturing to return to the U.S., with exemptions for companies already investing in U.S. production [11][12] - Major pharmaceutical companies have announced plans to increase investments in U.S. manufacturing, including companies like Eli Lilly, Novartis, and Roche [12][15] Global Supply Chain Dynamics - The global pharmaceutical manufacturing landscape has been shaped by cost-saving measures, with China and India becoming key players in raw material production [15][16] - The U.S. relies heavily on imports for raw materials, with 80% of its raw materials sourced from China and India [18] - The geopolitical climate is prompting a shift towards localized production, as companies seek to mitigate tariff and geopolitical risks [19]

Core Viewpoint - The Hang Seng Healthcare Index fell by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Recommendations - The report suggests focusing on companies with significant data releases at the upcoming ESMO conference in mid to late October, specifically mentioning Kangfang Biotech (09926), Kelun-Biotech (06990), and Rongchang Biotech (09995) [1] - The importance of timing and stock selection has increased following a broad rise in the innovative drug sector, with recommendations to gradually build positions during market corrections [1] Group 3: Sector Focus - For the innovative drug sector, the report highlights companies such as 3SBio (01530) and Eucure Biopharma-B (06996) as having rich short-term catalysts and undervalued core products, while companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are noted as significantly undervalued with clear long-term growth logic [1] - In the CXO sector, the report points to leading companies benefiting from high downstream demand and marginal recovery in financing, specifically mentioning WuXi AppTec (02268) [1]

Core Viewpoint - The Hang Seng Healthcare Index declined by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Opportunities - Domestic investors are focusing on rebound opportunities, while foreign investors are increasing positions in innovative drug targets with high long-term potential and current cost-effectiveness [1] - The innovative drug guarantee model is gradually taking shape, which is expected to alleviate challenges such as hospital access and reimbursement difficulties for companies [1] Group 3: Upcoming Events - The ESMO conference will be held in mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] Group 4: Stock Recommendations - The importance of timing and stock selection has increased after a broad rise in the innovative drug sector, with recommendations to gradually build positions during sector pullbacks [1] - Specific recommendations include: 1. Innovative drugs: 3SBio (01530), Eucure Biopharma-B (06996) with rich short-term catalysts and undervalued long-term growth logic [1] 2. CXO: Leaders in high-demand segments benefiting from improved financing conditions, such as WuXi AppTec (02268) [1]